The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Nitric Oxide Donor, NOR-3, Increased Expression of Cyclooxygenase-2, but not of Cyclooxygenase-1 in Cultured VSMC

  • Lee, Dong-Hyup (Departments of Thoracic & Cardiovascular Surgery, College of Medicine, Yeungnam University) ;
  • Park, Ji-Eun (Departments of Pharmacology, College of Medicine, Yeungnam University) ;
  • Kang, Young-Jin (Departments of Pharmacology, College of Medicine, Yeungnam University) ;
  • Lee, Kwang-Youn (Departments of Pharmacology, College of Medicine, Yeungnam University) ;
  • Choi, Hyoung-Chul (Departments of Pharmacology, College of Medicine, Yeungnam University)
  • Published : 2006.06.21
Download PDF
⟨ Previous Next ⟩

Abstract

NO and cyclooxygenase-2 (COX-2) are contributes to vascular inflammation induced by various stimulation. The mechanism, which explains a linkage between NO and COX-2, could be of importance in promoting pathophysiological conditions of vessel. We investigated the effects of NO donors on the COX-l and COX-2 mRNA/protein expression, as well as the nitrite production in culture medium of vascular smooth muscle cell (VSMC). VSMC was primarily cultured from thoracic aorta of rat. In this experiments, COX-l and COX-2 mRNA/protein expressions were analysed and nitrite productions were investigated using Griess reagent. VSMC did not express COX-2 protein in basal condition (Nonlipopolysaccharide (LPS) stimulated). In LPS-stimulated experiments, after 3 hours of NO donor pretreatment, LPS $10{\mu}g/ml$ was treated for 24 hours. COX-l protein expressions were unchanged by SNP and NOR-3. NOR-3 significantly increased COX-2 mRNA/protein expression under LPS stimulation. In contrast, SNP did not increase COX-2 mRNA/protein expression under LPS stimulation. Nitrite production was higher in NOR-3 treatment than SNP treatment under LPS stimulation. These results suggest that the expression of COX-2 in VSMC is regulated by NOR-3, COX-2 expressions were depending on the types of NO donor and LPS stimulation in VSMC.

Keywords

References

  1. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci 76: 2315- 2328, 2005 https://doi.org/10.1016/j.lfs.2004.10.042
  2. Ajmone-Cat MA, Nicolini A, Minghetti L. Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitro-flurbiprofen, on prostaglandin E2, interleukin-1$\beta$, and nitric oxide synthesis by activated microglia. J Neurosci Res 66: 715-722, 2001 https://doi.org/10.1002/jnr.10038
  3. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002 https://doi.org/10.1002/jcp.10068
  4. Choi HC, Lee KY. CD14 glycoprotein expressed in vascular smooth muscle cells. J Pharmacol Sci 95: 65-70, 2004 https://doi.org/10.1254/jphs.95.65
  5. Choi HC, Lee SG, Kim JH, Kim JY, Sohn UD, Ha JH, Lee KY, Kim WJ. Lipopolysaccharide inhibits proliferation of the cultured vascular smooth muscle cells by stimulating inducible nitric oxide synthase and subsequent activation of guanylate cyclase. Korean J Physiol Pharmacol 5: 343-351, 2001
  6. Chwalisz K, Garfield RE. Nitric oxide as the final metabolic mediator of cervical ripening. Hum Reprod 13: 245-248, 1998 https://doi.org/10.1093/humrep/13.2.245
  7. D'Acquisto F, Mairui MC, Cristofaro F, Carnuccio R. Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-$\kappa$B and nuclear factor interleukin-6 activation. Naunyn Schmiedebergs Arch Pharmacol 364: 157-165, 2001 https://doi.org/10.1007/s002100100435
  8. Davidge ST, Baker PN, Laughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 77: 274 -283, 1995 https://doi.org/10.1161/01.RES.77.2.274
  9. Ekerhovd E, Bullarbo M, Andersch B, Norström A. Vaginal administration of the nitric oxide donor isosorbide mononitrate for cervical ripening at term: a randomised controlled study. Am J Obstet Gynecol 189: 1692-1697, 2003 https://doi.org/10.1016/S0002-9378(03)00865-2
  10. Festa A, Haffner SM. Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111: 2414-2415, 2005 https://doi.org/10.1161/01.CIR.0000167558.77793.E8
  11. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio E, Udagawa Y. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26: 1419-1428, 2005
  12. Nachtigal P, Kopecky M, Solichova D, Zdansky P, Semecky V. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 57: 197-203, 2005 https://doi.org/10.1211/0022357055353
  13. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68: 341-350, 2004 https://doi.org/10.1016/j.bcp.2004.03.029
  14. Nathan C, Xie Q. Nitric oxide synthase: roles, tolls, and controls. Cell 78: 915-918, 1994 https://doi.org/10.1016/0092-8674(94)90266-6
  15. Park YM, Won JH, Yun KJ, Ryu JH, Han YN, Choi SK, Lee KT. Preventive effect of Ginkgo biloba extract (GBB) on the lipopolysaccharide- induced expressions of inducible nitric oxide synthase and cyclooxygenase-2 via suppression of nuclear factor-kappaB in RAW 264.7 cells. Biol Pharm Bull 29: 985-990, 2006 https://doi.org/10.1248/bpb.29.985
  16. Perez-Sala D, Diaz-Cazorla M, Ros J, Jimenez W, Lamas S. Tetrahydrobiopterin modulates cyclooxygenase-2 expression in human mesangial cells. Biochem Biophys Res Commun 241: 7-12, 1997 https://doi.org/10.1006/bbrc.1997.7761
  17. Pfeilschifter J. Nitric oxide triggers the expression of proinflammatory and protective gene products in mesangial cells and the inflamed glomerulus. Nephrol Dial Transplant 17: 347-348, 2002 https://doi.org/10.1093/ndt/17.3.347
  18. Rodeberg DA, Chaet MS, Bass RC, Arkovitz MS, Garcia VF. Nitric oxide: an overview. Am J Surg 170: 292-303, 1995 https://doi.org/10.1016/S0002-9610(05)80017-0
  19. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 93: 1940-1947, 1994 https://doi.org/10.1172/JCI117185
  20. Shimomura-Shimizu M, Sugiyama KI, Muroi M, Tanamoto KI. Alachlor and carbaryl suppress lipopolysaccharide-induced iNOS expression by differentially inhibiting NF-kappaB activation. Biochem Biophys Res Commun 332: 793-799, 2005 https://doi.org/10.1016/j.bbrc.2005.05.024
  21. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthase (cyclooxygenase)-1 and -2. J Biol Chem 271: 33157- 33160, 1996 https://doi.org/10.1074/jbc.271.52.33157
  22. Szabo C, Mitchell JA, Thiemermann C, Vane JR. Nitric Oxidemediated hyporeactivity to noradrenalin preceds the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108: 786-792, 1993 https://doi.org/10.1111/j.1476-5381.1993.tb12879.x
  23. Takahiro S, Yoshinobu O, Junichi K, Takayuki F, Kenjiro K. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1$\beta$ -stimulated rat arortic smooth muscle cells. J Hyperten 20: 455- 461, 2002 https://doi.org/10.1097/00004872-200203000-00021
  24. Thomson AJ, Lunan CB, Cameron A, Cameron IT, Greer IA, Norman JE. Nitric oxide donors can induce ripening of the human uterine cervix: a randomised controlled trial. Br J Obstet Gynaecol 104: 1054-1057, 1997 https://doi.org/10.1111/j.1471-0528.1997.tb12066.x
  25. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 182: 591-595, 1990 https://doi.org/10.1016/0014-2999(90)90062-B
  26. Vane JR. COX-2 inhibitors: background knowledge for clinical use. Introduction. Inflamm Res 47: S77, 1998 https://doi.org/10.1007/s000110050283
  27. Vo PA, Lad B, Tomlinson JA, Francis S, Ahluwalia A. Autoregulatory role of endothelium-derived nitric oxide (NO) on Lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem 280: 7236-7243, 2005 https://doi.org/10.1074/jbc.M411317200
  28. Williams CS, DuBois RN. Prostagladin endoperoxide synthase: why two isoforms- Am J Physiol 270: G393-G400, 1996
  29. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 22: 176-181, 1997
  30. Yang T, Zhang A, Pasumarthy A, Zhang L, Warnock Z, Schnermann JB. Nitric oxide stimulates COX-2 expression in cultured collecting duct cells through MAP kinases and superoxide but not cGMP. Am J Physiol Renal Physiol 2006 (in print)